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ABSTRACT
Ventricular tachyarrythmia occurring in ischemic heart disease, dilated/hypertrophic cardiomyopathies or rare mono-
genic mutations of cardiac ion channels or associated proteins belong to the most frequent causes of sudden cardiac 
death (SCD). In further decades, next generation sequencing and bioinformatic analysis will become the gold standard 
of SCD risk stratification. At the moment, Sanger-sequencing is still obligatory in genetic diagnosis. A multiplex poly-
merase chain reaction (PCR) assay detecting eight SCD mutations in one reaction-tube was developed. To test the 
general validity of the assay, it was used with 12 patients, who had one or two of the eight mutations (LMNA, p.V256V; 
SCN5A, p.R1583C; RYR2, p.G1885E; MYH7, V606M; DSG2, p.T335A; KCNJ8, p.S422L; MYBPC, p.E441K; TNNT2, 
A38V). Thereafter, we tested the multiplex assay in a real diagnostic environment within a high risk family of several 
past SCD cases. This method allows efficient discrimination of multiple mutations by allele-specific PCR with standard 
PCR conditions. It relies on obtaining a PCR product specific to the mutation or wildtype—using primers that have the 
3´end base complementary to the DNA template site, i.e. a specific primer only permits amplification to take place when 
its 3´terminal nucleotide matches with its target sequence. The PCR products are further analyzed by length, with Tape 
Station®(Agilent Technologies, Germany), a high-fidelity capillary chromatography test. The novel multiplex PCR assay 
strategy could be a good additional test used for SCD risk stratification. Advantages of the test are high velocity and 
ease of implementation, low price and flexibility of application within cardiomyopathy families for screening purposes.
Keywords: sudden cardiac death, personalized medicine, point-of-care testing, PCR
INTRODUCTION
Sudden cardiac death (SCD) is an unexpected fatal event due to 
cardiac disorders- accounting for 100000 to 200000 annual deaths in 
Germany [1].The most frequent cause of SCD is ventricular tachyar-
rhythmia occurring in ischemic heart disease (ca. 75%–80%); dilated 
cardiomyopathy (idiopathic and post-myocarditis, ca. 10%–15%) or 
rare monogenic mutations in cardiac ion channels or associated proteins 
(1%–2%). The mechanism of arrhythmia in cardiomyopathy might be 
explained by structural or geometrical changes of heart muscle although 
genetic or epigenetic changes of trigger proteins like ion channels might 
be another distinct cause of arrhythmia [2-4]. Molecular diagnostics and 
genetic testing could be helpful in these cases, since protein changes may 
have a genetic background and occur frequently in a familial setting. In 
further decades, next generation sequencing and bioinformatic analysis 
will become the gold standard of SCD risk stratification. At the moment 
Sanger-sequencing is still necessary for genetic diagnosis. Therefore, 
we developed a flexible multiplex test for some SCD causing mutations 
for family screening purpose after a genetic testing was made with a 
positive result. The other family members can be tested with the de-
veloped multiplex allele-specific polymerase chain reaction (AS-PCR).
The AS-PCR allows the detection of known SNPs in minimally 
equipped laboratories. Newton et al. were the first group to describe 
the AS-PCR technique for known point mutations in 1989 [5]. This 
method relies on the formation of a PCR product on the basis that the 
nucleotide at the 3´-end of the primer complements perfectly, meaning 
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one primer is designed to mismatch one allele and match the other allele 
perfectly. Thus, one allele is preferably amplified. After Newton et al. 
[5] developed the AS-PCR, which permits the differentiation of any 
known mutation in genomic DNA, other innovative approaches were 
developed to detect specific PCR products. For example, “melting 
curve analysis” [6] which needs nucleic acid strains, or “hybridization 
by specifically labeled probes” [7]. AS-PCR is used in many areas of 
study such as the detection of genetic disorders [8-11], microbiology 
research [12], pharmacogenetics [13] and genotyping [14]. For every 
AS-PCR reaction, only one SNP can be examined.
In this work, we describe a new inexpensive multiplex AS-PCR 
method that allowed us to detect various known mutations, which are 
associated with SCD.
MATERIALS AND METHODS
Literature research and bioinformatics
Literature research was performed in PubMed under the category 
ClinVar with the key words “sudden cardiac death” and “pathogenic”. 
This database is a web-based overview of systemic meta-analysis and 
collective data and it is regularly updated with genetic association 
studies. The database listed 130 relevant mutations which are asso-
ciated with SCD. Not all of them are real pathogenic; some of them 
are unclassified because of contradictory statements. For our purpose, 
it is fully adequate because our main focus is the development of a 
cost-efficient method for the diagnostic of familial SCD. This list was 
matched with a gene bank comprising many cases of SCD and cardio-
myopathies (Benjamin Meder group, Cardiology, Internal Medicine III, 
University of Heidelberg). Within this gene bank, the DNA of 7 patients 
matched the criteria mentioned above found in the literature research. 
Five additional patients originated from our outpatient resources. The 
5 patients are members of a huge family with a strong history of SCD 
(Fig. 1A). The index patient (III.3), a 28-year-old Caucasian male 
presented to our medical outpatient resource because of sharp pain in 
the breast. Echocardiography revealed normal left ventricular function 
but an ECG with atrioventricular block pattern (degree I). Because of 
a positive family-history of SCD, we advised him to undergo genetic 
testing. The genetic testing with NGS revealed two mutations: LMNA, 
c.768G>A and SCN5A, c.4747C>T. Overall we had 12 patients with 
one of the 130 mutations mentioned above (Table 1).
Primer design
Primers for the multiplex AS-PCR were designed using Primer3 web 
version 4.0.0 software and were scanned for uniqueness using NCBI 
BLAST search engine. The primer oligos were synthesized by Biomers 
(Germany, Ulm). For each mutation, the primer set included a reverse 
common primer (R) and two forward allele-specific primers (Fwt and 
Fmt), with the 3´ terminal base of each specific primer matching the 
wildtype or the mutant allele. The primers were designed to have a 
length of 19–28 nucleotides and to amplify fragments ranging from 
180 to 600 bp and the fragments differ from each other between 30–62 
bp. An unspecific mismatch was added to the allele-specific forward 
primer end to increase the allele specificity because only one mutation 
was insufficient to achieve the wanted level of discrimination. It is 
known that a single mismatch, at or near the 3´end can effect PCR 
more strongly than at other positions [14,15]. According to “Current 
Protocols in Human Genetics” [16], the strength of mismatch pairing 
are: “None”: AT, GC; “weak”: CA, GT; “medium”: AA, GG; “strong”: 
CC; “maximum”: GA, CT, TT (Table 1). As a general rule for the 
primer design, if the 3´end mismatch is a strong one, a weak secondary 
mismatch has to be incorporated. To distinguish between complete PCR 
failures from an informative no-amplification result, an internal control 
was added to WT and MT sample. The internal control for WT and MT 
sample consisted of the same primer pair with an amplicon length of 
600 bp and without additional mismatch. The position of the primer 
pairs has to be chosen carefully—making sure that a different product 
length is to be formed for each mutation. Differentiation between the 
eight mutations and the internal control is by size length of amplifi-
cation products. The principle of the new modified AS-PCR method 
is schematically presented in Figure 2. The primer pairs were at first 
used at the same concentration of 0.4 µM, but with equimolar primer 
concentrations uniform amplification signals for all fragments was not 
given therefore the concentration of some primer pairs were reduced 
or increased (Table 1).
PCR
The Qiagen Multiplex PCR Plus Kit was used containing the Hot-
StarTaq Plus DNA Polymerase without any 3´-5´exonuclease activity 
because using a DNA Polymerase with 3´-5´exonuclease activity shows 
false positive results (data not shown). Since the assay comprises two 
multiplex reactions, the primer sequence has to be designed with similar 
reaction kinetics. A C/G content of 40%–60% is suggested as general 
guideline for specific annealing. PCR for WT and MT tubes were car-
ried out using a thermal cycler (Eppendorf Mastercycler, vapo.protect, 
Germany). Final volume of PCR reaction was 25 µl. The mixture of 
PCR comprised 1 × Multiplex PCR Master Mix (Qiagen, Germany), 
2.5 µl Primer Mix, 150 ng DNA, 0.2 µl Taq polymerase. PCR was 
performed within 5 min of denaturation at 95°C, 35 cycles of 95°C for 
30 s, annealing at 65°C for 90 s, 72°C for 30 s, and a final extension 
at 68°C for 10 min.
Electrophoresis
After PCR, the products are separated and analyzed by electrophoresis 
with the Agilent 2200 TapeStation system (Agilent, Germany) with the 
High Sensitivity D1K Kit according to the manufacturer information 
and the band patterns should look like stairs (Fig. 1E).The method was 
validated by direct DNA sequencing or next generation sequencing.
For sanger sequencing, all mutated exons were amplified by poly-
merase chain reaction. After purification of the PCR products with 
magnetic bead-based AmPure XP system (Beckman Coulter), PCR 
fragments were sequenced in both directions using the GenomeLab™ 
DTCS Quick Start Kit and GeXP Genetic Analysis System (Beckman 
Coulter).
Next generation sequencing was performed on an Ion Torrent 
PGM (Life Technologies) according to information delivered by man-
ufacturer. The study was conducted according to the recommendations 
of the Declaration of Helsinki, and was approved by the University of 
Heidelberg Human Ethics Committee.
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Figure 1. Pedigree and summary of the multiplex AS-PCR results. A. Family of the index patient (III.3). Uncle (II.2) and aunt (II.7) was diagnosed 
with dCMP and had to undergo heart transplantation. Father (II.3) (33 years) and grandfather (I.2) (56 years) died of SCD. B. The electropherogram 
profiles from patient one (III.3) from the dCMP and SCD family. Lower: lower marker; Upper: upper marker. C. Electropherogram from patient #10. D. 
Electropherogram from negative control. E. Summary of the product sizes of all twelve patients with SD of read lengths versus expected sizes. Error 
bars represent the standard deviation of all PCR products in the WT sample from all twelve patients. F. Summary of averaged concentrations from all 
PCR products from all twelve patients in the WT sample and the error bars represent the standard deviation.
RESULTS
Figure 1B and 1C shows the electropherograms of patient #1 (in-
dex patient; III.3), patient #10 (not from the index patient family) and 
negative control. WT samples from both patients showed nine peaks 
with the expected product sizes. The control peak at 600 bp was de-
tected in the WT and MT sample. MT sample from patient #1 (index 
patient, III.3) showed two extra peaks with the sizes of 460 bp and 
414 bp (Fig. 1B). This means that patient #1 had the LMNA and the 
SCN5A mutation, both mutations are heterozygous. Because of these 
findings, some other members of the family decided to make a genetic 
testing. We used our developed test to screen the members if they had 
these two specific mutations as well and the result was: Three members 
(II.2; II.7; III.7) had only the LMNA mutation. Two of them (II.2; II.7) 
had already a heart transplantation. The third member (III.7) with the 
LMNA mutation had to make echocardiography controls on an annual 
basis to enable to intervene more rapidly whenever anomalies are found 
(Fig. 1A). Seven additional patients with known mutations were tested 
with the developed assay. As an example, we just displayed one of the 
seven patients. MT sample of patient #10 (Fig. 1C) showed besides 
the control peak (617 bp) an additional peak with the size of 358 bp 
which represent the MYH7, c.1816G>A mutation, meaning that the 
mutation is heterozygous.
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Figure 2. Schematic presentation of the multiplex AS-PCR method. A. Two reaction tubes were necessary for the assay. Content of the tubes: common 
reverse primer and different forward primer of all 8 + 1 control amplicons. The control primers (internal quality control) are the same primer pair in WT 
and MT tubes, taq-polymerase without 3´-5´exonuclease activity and template DNA. B. As an example, the mutation used here is a G->A substitution, 
but this method can be used for all other single base substitutions. Only a perfectly fitting forward primer guarantees an amplicon. This means: If the G 
allele is present, only the WT forward primer can bind to the DNA template and an amplicon, which presents the G allele, is generated. An A allele ampl-
icon is generated when the MT forward primer can bind to the DNA. If the person is heterozygous at this position, two amplicons occur. Allele-specificity 
was increased by introducing a mismatch at position 2—counting from the 3´terminus. By positioning the reverse primer at different distances from the 
mutation, the nine amplicons differ in length, allowing them to be discriminated by gel electrophoresis. Only the control forward primer has no additional 
mismatches. The mutant specific nucleotide forms a base pairing only with the mutant allele. In contrast, the wildtype-specific nucleotide forms a base 
pairing only with the wildtype allele. C. After performing the multiplex PCR, products of both tubes are separated by Tape Station. Each of the nine am-
plicons was of a different length. Therefore, the mutations were detected on the basis of the patterns of their peak size.
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Figure 3. DNA sequencing results from patient 1(index patient) for LMNA, p.Val256Val (A) and SCN5A, p.Arg1583Cys (B).
In all 12 patients’ electropherograms, as well in the negative control 
(Fig. 1D) electropherograms, where the DNA was replaced with water, 
are undefined peaks in the region of 30–100 bp with a concentration 
higher than 0.4 ng/µl visible. A concentration higher than 0.4 ng/µl is 
the baseline for including in the analysis. In the region 200–700 bp 
where the expected products are located almost no background signals 
were visible thus showing the specificity of the primers (Fig. 1D). 
The unspecific peaks in the region of 30–100 bp had to be defined as 
artifacts, because the negative control electropherograms (Fig. 1D) 
showed the same unspecific peaks, although there was no DNA in the 
sample—deriving possibly from primer-primer interactions. The geno-
types which were detected by help of this new multiplex AS-PCR assay 
were in 100% accordance with the sequencing results, Figure 3 shows 
DNA sequences for LMNA, p.Val256Val and SCN5A, p.Arg1583Cys 
mutations from patient #1 elicited by Sanger technology as examples 
for the validation method.
To determine the sizing accuracy of the assay, PCR products from all 
12 patients were analyzed and the corresponding sizes compared to the 
expected product sizes are summarized as a mean value and standard 
deviation was calculated (Fig. 1E). In general, the detected amplicons 
were 8–25 bp bigger than the excepted sizes but this did not distort the 
analysis because in the detected electropherograms all expected peaks 
are clearly separated from each other and above the background signal. 
Sizing precision was assessed by calculating the standard deviation 
(SD) from the size values obtained from all PCR-products in the WT 
samples of all twelve patients. The SD of the mean of amplicon size 
measurements was less than 6 bp, which demonstrates a stable deter-
mination of mutations and a valid determination of amplicon sizes.
Multiplex PCR with all primers produced the highest product con-
centration amounts of MYH7 and LMNA followed from SCN5A and 
control. All other amplicon concentration amounts were almost at the 
same concentration level. On the whole, the detected peak concentration 
of the MT samples was much lower compared to the WT samples. For 
example, in patient #10, the MYH7 peak in WT sample had a concentration 
of about 4.23 ng/µl and in the MT sample just 2.25 ng/µl but this did not 
disturb the analysis because the MT electrophero gram showed a clearly 
separated MYH7 peak without any background signals. Moreover, the 
concentration of this peak was higher than 0.4 ng/µl. All tests which 
were performed showed no false-positive results.
For peak formation, some factors are more critical than others: (1) 
Products smaller than 180 bp were not included because the smallest 
product expected was184 bp; (2) The concentration of the peaks must 
be higher than 0.4 ng/µl; and (3) Peaks should be clearly visible above 
the background signal.
Genetic analysis revealed heterozygous mutations of LMNA and SC-
N5A genes—same as with multiplex AS-PCR method in patient #1. Only 
the validation sequencing results of patient #1 are shown, as examples 
for all other patients. The LMNA gene allele included a substitution of 
G for A at position 768 (Fig. 3A) and the SCN5A gene allele included 
a substitution of C for T at position 4747 (Fig. 3B).
In the age of personalized medicine, fast, low-cost and reliable SNP 
detection methods attract increasing interests. In cardiovascular diseases, 
genetic testing and molecular diagnostics may be useful for preventive 
and therapeutic decisions in early stage of disease progression. In this 
way, family counseling will become much easier and better.
DISCUSSION
At the moment Sanger-sequencing is the gold standard in genetic 
testing. Sanger-sequencing is very time consuming, so is next gener-
ation sequencing. In some cases, the patient has to wait months to get 
the results, and then the result is “no mutation” is found. Both methods 
are based on sequencing of whole gene areas. With our newly devel-
oped multiplex AS-PCR the simultaneous and rapid genetic testing of 
eight SCD variants is finished within three hours and the results are 
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available within one day because only known mutations are tested, so 
the patient does not need to worry about long period delays of uncer-
tainty. The multiplex AS-PCR can be used in family diagnostics, if one 
family member underwent a genetic testing and get a positive NGS 
result, the other family members can be analyzed with our developed 
test. In our case, the index patient (III.3) had two mutations: LMNA, 
p.V256V and SCN5A, p.R1583C.Therefore, we decided to insert an 
implantable cardioverter defibrillator (ICD), because of the incidence 
of two mutations and their high risk to get arrhythmia. The new assay 
combines two methods: multiplex PCR with AS-PCR. This improved 
method requires only two PCR tubes to differentiate between wildtype 
and mutant allele in eight different regions of DNA. An optimization 
procedure was implemented because equimolar primer concentrations 
and false annealing temperatures showed irregular fragment amplifi-
cations. Finally, a combination of different primer concentrations and 
an annealing temperature of 65°C achieved the expected sensitivity 
and specificity (Table 1).
Table 1. Mutations which are detectable with the multiplex AS-PCR*.
Gene Mutation Primer name Primer sequence 5’-3’ Product 
size (bp)
Conditions Concentration 
(µM)
TNNT2
(NM_000364.3)
c.113C>T (p.Ala-
38Val)
TNNT2_Fwt
TNNT2_Fmt
TNNT2_R
TCCAGAGCAGGAGGAGGCTGC
TCCAGAGCAGGAGGAGGCTGT
GAGTCAGGTGCACATGGGAAAGC
184 • Primary familial 
hypertrophic cardio-
myopathy
• Cardiomyopathy
• Increased left 
ventricular wall 
thickness
0.5
MYBPC3
(NM_000256.3)
c.1321G>A 
(p.Glu441Lys)
MYBPC3_Fwt
MYBPC3_Fmt
MYBPC3_R
CCAGTGCGTGGTGGGTGTCG
CCAGTGCGTGGTGGGTGTCA
CTTCACACTCAAACTCCACCCGC
213 • Primary familial 
hypertrophic cardio-
myopathy
• Cardiomyopathy
0.4
KCNJ8
(NM_004982.3)
c.1265C>T 
(p.Ser422Leu)
KCNJ8_Fwt
KCNJ8_Fmt
KCNJ8_R
CTCCAGAAGGAAATCAAAACAC-
GTC
CTCCAGAAGGAAATCAAAACAC-
GTT
TCACTGCGAATTCTACATGTATGA
260 • Brugada syndrome 0.5
DSG2
(NM_001943.3)
c.1003A>G
(p.Thr335Ala)
DSG2_Fwt
DSG2_Fmt
DSG2_R
GATGCTCAAACTAACGAAG-
GAATTGGGA
GATGCTCAAACTAACGAAG-
GAATTGGGG
TGCAAGAAAGCCTGGAAAT-
GAGCT
311 • Arrhythmogenic 
right ventricular 
cardiomyopathy
• Cardiomyopathy
0.4
MYH7
(NM_000257.3)
c.1816G>A 
(p.Val606Met)
MYH7_Fwt
MYH7_Fmt
MYH7_R
AGGATCCTCTCAATGAGACTG-
GCG
AGGATCCTCTCAATGAGACTG-
GCA
AAGAAGCATCAGTGTGGGGAGGT
351 • Familial hypertro-
phic cardiomyop-
athy 1
• Primary familial 
hypertrophic cardio-
myopathy
• Cardiomyopathy
0.4
SCN5A
(NM_198056.2)
c.4747C>T
(p.Arg1583Cys)
SCN5A_Fwt
SCN5A _Fmt
SCN5A _R
GTCAAGCTGGCTGCCCGGC
GTCAAGCTGGCTGCCCGGT
CATCCTTGAAGCTCTCTAAG-
CAGTT
390 • Brugada syndrome 0.3
LMNA
(NM_170707.3)
c.768G>A
(p.Val256Val)
LMNA_Fwt
LMNA_Fmt
LMNA_R
GCCCAGCATGAGGACCAGTTG
GCCCAGCATGAGGACCAGTTA
CATCCGGCCCAGACTCTAGG
452 • Cardiomyopathy 0.3
RYR2
(NM_001035.2)
c.5654G>A 
(p.Gly1885Glu)
RYR2_Fwt
RYR2_Fmt
RYR2_R
GCTGGTGAGGAAGAAGCCAATGG
GCTGGTGAGGAAGAAGCCAATGA
CTGTAGAAGCTGAGGTGGGAGGA
560 • Arrhythmogenic 
right ventricular 
cardiomyopathy
0.3
TNNT2
(NM_000364.3)
Ex 17 Control_F
Control_R
TCCAGCTATCCCATTCCTCCTTG
CGCCTCAGTTTCTCTCTCTCTCT
600 • Control 0.3
*Precisely these eight different mutations were included to the test because only from these mutations patients' DNA were available (source: Orphanet, 
PubMed). Also the sequence of primers used for analysis, expected product sizes and concentrations.
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The multiplex AS-PCR has the advantage of the minimal hands-on-
effort and the handling is simple it can be developed to a point-of-care 
test (POC) with ready-to-use WT and MT samples. Hitherto, in the 
field of molecular genetics there are only a few POC tests available, 
because of the interpretation of the results and the many method steps. 
For prediction of sudden cardiac death burden, a “point-of-care test” 
is best of all possible test strategies for several reasons: (1) The test 
has to be fast in order to avoid cases of SCD during lab procedure 
that can take up to 3 months in some different settings; (2) The test 
has to be inexpensive because of the severity of consequences—it has 
to be accessible to all social layers independently from the insurance 
system—perhaps also for people in the third world countries; and (3) 
The diagnosis of sudden cardiac death burden hast to be based onto 
unequivocal research results—only some few mutational results might 
fit this condition, arising from former intensive bioinformatics. Other 
SNPs are unacceptable, since consequences for affected patients are 
severe from a psychological point of view, but also from putative 
treatments, i.e. implantation of heart rhythm devices.
With this study, we could establish a cost-effective, rapid and re-
producible method, interesting for personalized medicine, as shown in 
our dCMP family. Thus the study is designed as a “proof-of-concept” 
study with the aim to show if a modified form of AS-PCR can detect 
known SCD mutations the case numbers can keep low.
The new multiplex AS-PCR assay could be a good additional test 
for SCD risk stratification for families with positive SCD history, but 
it is limited to only known mutations not excluding other mutations in 
other disease-causing genes.
To conclude, during past decades, a number of characteristics have 
been described to stratify cardiac patients to their risk of SCD. These 
tests address different cardiac (e.g., pump function) and non-cardiac 
factors (e.g., depression). The AS-PCR assay could serve as an addi-
tional test for familial SCD-burdened patients. Complex bioinformatics 
strategies are restricted to the initial design since the assay just detects 
well-known SCD mutations. Ease of implementation and further sim-
plification of some steps within the test algorithm allow usage of the 
test as a standardized POC tool.
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